Method of action:
Medically reviewed by Kovalenko Svetlana Olegovna, PharmD. Last updated on 2020-03-30
Attention! Information on this page is intended only for medical professionals! Information is collected in open sources and may contain significant errors! Be careful and double-check all the information on this page!
Top 20 medicines with the same components:
Keyou Cream is indicated for the treatment of herpes simplex virus infections of the lips and face (herpes labialis) in adults (including older people) and children over 12 years of age.
Immunocompromised patients: Keyou Cream is not recommended for use in immunocompromised patients; such patients should consult a physician concerning the treatment of any infection.
Adults (including older people) and children over 12 years of age
Keyou Cream should be applied at approximately two hourly intervals during waking hours, (approximately 8 times a day). Treatment should be continued for 4 days. If the condition gets worse or does not improve after 4 days treatment, seek medical advice.
Treatment should be started as early as possible after the first sign of an infection.
Children (under 12 years):
The safety and efficacy of Keyou Cream in children below 12 years of age have not been established.
No data are available.
The cream should only be used on cold sores on the lips and around the mouth. It is not recommended for application to mucous membranes (e.g. in the eyes, mouth, or nose or on the genitals). Particular care should be taken to avoid application in or near the eyes.
Patient with particularly severe cold sores should be encouraged to seek medical advice.
Patients should be advised to avoid transmitting the virus, particularly when active lesions are present.
Immunocompromised patients (e.g. AIDs patients or bone marrow transplant recipients) should be encouraged to consult a physician in case oral therapy is indicated.
The cream contains cetostearyl alcohol, which may cause local skin reactions (e.g. contact dermatitis). It also contains propylene glycol, which may cause skin irritation.
Keyou Cream has no influence on the ability to drive and use machines.
Summary of the safety profile
Keyou Cream has been well-tolerated in human studies. Clinical trial experience has shown that there was no difference between Keyou Cream and placebo in the rate or type of adverse reactions reported.
The most common events are application site adverse events.
Tabulated list of adverse reactions
Adverse reactions are listed below by system organ class and frequency. Frequencies are defined as: very common (>1/10); common (>1/100 to <1/10); uncommon (>1/1,000 to <1/100); rare (>1/10,000 to <1/1,000); very rare (<1/10,000); unknown (cannot be estimated from available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
General disorders and administration site condition: Common
Application site reactions (including skin burning sensation, pain of skin, hypoaesthesia)
Post-marketing surveillance has revealed the following adverse events (all reactions were either localised or generalised). Adverse events from post- marketing experience are difficult to calculate a frequency and therefore the events are listed as unknown frequency.
Immune System disorders:
Skin and subcutaneous disorders:
dermatitis allergic (including rash, pruritus, blisters and oedema)
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard.
No untoward effects would be expected even if the entire contents of a container of Keyou Cream were ingested orally; penciclovir is poorly absorbed following oral administration. However, some irritation in the mouth could occur. No specific treatment is necessary if accidental oral ingestion occurs.
Pharmacotherapeutic group: Topical antiviral agent, ATC code: D06BB06
Mechanism of action
Penciclovir has demonstrated in vivo and in vitro activity against herpes simplex viruses (types 1 and 2) and varicella zoster virus. In virus-infected cells penciclovir is rapidly and efficiently converted into a triphosphate (mediated via virus-induced thymidine kinase).Penciclovir triphosphate persists in infected cells for more than 12 hours where it inhibits replication of viral DNA and has a half-life of 9, 10 and 20 hours in cells infected with varicella zoster virus, herpes simplex virus type 1 and herpes simplex virus type 2 respectively. In uninfected cells treated with penciclovir, concentrations of penciclovir triphosphate are only barely detectable. Accordingly, uninfected cells are unlikely to be affected by therapeutic concentrations of penciclovir.
Clinical efficacy and safety
In clinical studies, Fenistil treated patients healed 30% faster than placebo (up to one day earlier), pain resolution was 25-30% faster (median improvement of up to one day) and infectivity resolved up to 40% faster (one day earlier) than placebo.
Following application of Keyou Cream in a human volunteer study at a daily dose of 180mg penciclovir (approximately 67 times the proposed daily clinical dose), to occluded and abraded skin for 4 days, penciclovir was not quantifiable in plasma and urine.
Topical application of 5% Keyou Cream for 4 weeks to rats and rabbits was well tolerated. There was no evidence of contact sensitisation in guinea pigs.
A full programme of studies has been completed using intravenous penciclovir. These studies did not raise any safety concerns regarding topical use of Keyou Cream. There is a minimal systemic absorption of penciclovir following topical administration.
Genotoxicity and Reproductive toxicity
Animal studies have not shown any embryotoxic or teratogenic effects with penciclovir given intravenously (at doses greater than 1200 times those recommended for clinical use via topical application), nor were there any effects on male and female fertility and general reproductive performance (at doses greater than 1600 times those recommended for clinical use via topical application). Studies in rats show that penciclovir is excreted in the breast milk of lactating females given oral famciclovir (famciclovir; the oral form of penciclovir, is converted in vivo to penciclovir).
The results of a wide range of mutagenicity studies in vitro and in vivo indicates that penciclovir does not pose a genotoxic risk to man.
Any unused product or waste material should be disposed of in accordance with local requirements.